Rizwan Hassan
Neurology · Hutchinson, KSNPI 1174524003
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,984 and has fallen 96.8% since, to $64 in 2025.
Across 177 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$783
- Biogen$499
- Amgen$362
- Neurocrine Biosciences, Inc.$349
- EMD Serono, Inc.$206
- UCB, Inc.$168
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,57498%
- Education$902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 41 | $783 |
| Biogen | 27 | $499 |
| Amgen | 11 | $362 |
| Neurocrine Biosciences, Inc. | 10 | $349 |
| EMD Serono, Inc. | 17 | $206 |
| UCB, Inc. | 9 | $168 |
| AstraZeneca | 3 | $140 |
| Jazz Pharmaceuticals Inc. | 3 | $123 |
| Lilly USA, LLC | 7 | $116 |
| Johnson & Johnson | 1 | $112 |
| Argenx US, Inc. | 1 | $100 |
| Supernus Pharmaceuticals, Inc. | 6 | $93 |
| AbbVie(2 entities) | 5 | $83 |
| Sanofi | 4 | $79 |
| Novartis | 3 | $63 |
| Avanir Pharmaceuticals, Inc. | 5 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $52 |
| Travere Therapeutics, Inc. | 7 | $47 |
| Genentech USA, Inc. | 3 | $46 |
| Kyowa Kirin, Inc. | 2 | $36 |
| Eisai Inc. | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Tanabe Pharma America, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Medtronic | 1 | $15 |
| Livanova USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,664 in reported general payments places this provider in the 70th percentile of 131 neurology providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 12 | $16,965 |
| Donepezil Hcl | 19 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact | $168 | $16,96512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 131 neurology providers in Kansas.
Other neurology in Hutchinson
- Khawla AbusamraHutchinson$5K
- William MalloneeHutchinson$2K
- Dustin HarkerHutchinson$1K
- Ivan OsorioKansas City$101.7M
- Jeffrey KaplanLenexa$1.9M
- Rajesh PahwaKansas City$889K
- Sheetal MalikTopeka$137K
- Richard DubinskyKansas City$122K
- Barbara Jean OttleyHays$116K
- Jeffrey BurnsKansas City$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.